Scholarlink

The author of this chapter and book also has a whole book on chemotherapy for infants and neonates published, and she thinks it is interesting that published information about chemotherapy in neonates and infants, although very scattered, is still more common than published information on treating children undergoing hormonal protocols in gender dysphoria. The author attributes this fact to the hormonal protocols to change children’s appearance as being relatively new, while Europe in 1500 was already using arsenic, largely, to treat cancer. Also, neoplastic diseases were documented in the paleopathological literature: histiocytoma in ancient Egypt, osteoclastoma in England and Italy, Hand-Schuller-Christian disease in a prehistoric Native American from New York State, eosinophil granuloma in a prehistoric Native American child from Illinois, and possible Ewing’s sarcoma in a juvenile skull from Bronze Age of Tartaren, Spain. Pediatric medical transition began in the Netherlands, which had offered adult treatment in an academic hospital starting in the 1970s, with the costs of a medical transition reimbursed through the Dutch national health insurance system, and the availability of comprehensive and reliable medical records gave clinicians the opportunity to study how patients managed. A paper detailing the results was published in 1988: “Sex Reassignment Surgery: A Study of 141 Dutch Transsexuals.” It is really hard to collect information on the subject of treating cancer in these children since this information is very absent, and when present, it is not focused on the chemotherapy protocols, treatments and drugs but on psychology and in the transitioning hormonal protocol. We need that healthcare professional specialists in pediatric oncology start to publish their experiences treating transsexual children and the results (Schmidt C. The blame game. In: Schmidt C (ed) The invisible hand of cancer. Springer, Cham. https://doi.org/10.1007/978-3-031-45774-6_1 , 2023; Capasso LL. Int J Cancer 113:2–13. https://doi.org/10.1002/ijc.20610 , 2005; Department of Health and Human Services: treatment for pediatric gender dysphoria: review of evidence and best practices, 2025).

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Pediatric Oncological and Hematological Treatment of Children in Hormone Therapy for Gender Dysphoria

  • 章节

  • 发表日期：

    2025年

查看全文
  • Carolina Witchmichen Penteado Schmidt

摘要

The author of this chapter and book also has a whole book on chemotherapy for infants and neonates published, and she thinks it is interesting that published information about chemotherapy in neonates and infants, although very scattered, is still more common than published information on treating children undergoing hormonal protocols in gender dysphoria. The author attributes this fact to the hormonal protocols to change children’s appearance as being relatively new, while Europe in 1500 was already using arsenic, largely, to treat cancer. Also, neoplastic diseases were documented in the paleopathological literature: histiocytoma in ancient Egypt, osteoclastoma in England and Italy, Hand-Schuller-Christian disease in a prehistoric Native American from New York State, eosinophil granuloma in a prehistoric Native American child from Illinois, and possible Ewing’s sarcoma in a juvenile skull from Bronze Age of Tartaren, Spain. Pediatric medical transition began in the Netherlands, which had offered adult treatment in an academic hospital starting in the 1970s, with the costs of a medical transition reimbursed through the Dutch national health insurance system, and the availability of comprehensive and reliable medical records gave clinicians the opportunity to study how patients managed. A paper detailing the results was published in 1988: “Sex Reassignment Surgery: A Study of 141 Dutch Transsexuals.” It is really hard to collect information on the subject of treating cancer in these children since this information is very absent, and when present, it is not focused on the chemotherapy protocols, treatments and drugs but on psychology and in the transitioning hormonal protocol. We need that healthcare professional specialists in pediatric oncology start to publish their experiences treating transsexual children and the results (Schmidt C. The blame game. In: Schmidt C (ed) The invisible hand of cancer. Springer, Cham. https://doi.org/10.1007/978-3-031-45774-6_1 , 2023; Capasso LL. Int J Cancer 113:2–13. https://doi.org/10.1002/ijc.20610 , 2005; Department of Health and Human Services: treatment for pediatric gender dysphoria: review of evidence and best practices, 2025).